1 Immunogenicity and reactogenicity against the SARS-CoV-2 variants following 2 heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy 3 4 Thai adults. 5 Suvimol Niyomnaitham^{1,2}, Zheng Quan Toh^{3,4}, Patimaporn Wongprompitak⁵, Laddawan 6 Jansarikit⁶, Kanjana Srisutthisamphan⁷, Sompong Sapsutthipas⁸, Yuparat Jantraphakorn⁷, 7 Natthakarn Mingngamsup⁸, Paul V Licciardi^{3,4}, Kulkanya Chokephaibulkit^{1,9} 8 9 ¹ Siriraj Institute of Clinical Research, Bangkok, Thailand 10 ² Department of Pharmacology, Faculty of Medicine, Siriraj Hospital, Mahidol University, 11 12 Bangkok, Thailand ³ Murdoch Children's Research Institute, Parkville, Victoria, Australia 13 ⁴ Department of Pediatrics, The University of Melbourne, Parkville, Victoria, Australia 14 ⁵ Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, 15 Bangkok, Thailand 16 ⁶ Health Systems Research Institute (HSRI), Nonthaburi, Thailand 17 ⁷ National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science 18 Development Agency (NSTDA), Pathum thani, Thailand 19 ⁸ Department of Medical Sciences, Institute of Biological Products, Bangkok, Thailand 20 ⁹ Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, 21 Bangkok, Thailand 22 23

24 Corresponding author:

25 Kulkanya Chokephaibulkit, MD NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26	Professor of Pediatrics,
27	Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University
28	Siriraj Institute of Clinical Research (SICRES)
29	2 Wanglang Road, Bangkoknoi, Bangkok 10700, Thailand
30	Tel: (+66) 2-4141899; Fax: (+66) 2-4128243
31	E-mail: kulkanya.cho@mahidol.ac.th
32	
33	Abstract word count:
34	Manuscript Text word count:
35	Running head: COVID-19 heterologous series of BNT162b2, ChAdOx1, CoronaVac
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	

51 Abstract

We evaluated the immunogenicity and reactogenicity of heterologous COVID-19 primary 52 series vaccination schedules. Participants were randomized to one of seven groups that 53 54 received two-dose homologous BNT162b2 or heterologous combinations of CoronaVac, ChAdOx1 and BNT162b2, with 4 weeks interval. Of 210 participants, median age was 38 (19-55 60) years, 51% were female. The groups that received BNT162b2 as second dose induced the 56 57 highest virus-specific IgG response against the ancestral strain [BNT162b2: geometric mean concentration (GMC) 2133-2249, 95%CI 1558 to 3055; ChAdOx1: 851-1201, 95%CI 649 to 58 59 1522; CoronaVac: 137-225, 95% CI 103-286 BAU/mL], neutralising antibodies (NAb) against Beta and Delta, and interferon gamma response. All groups induced low to negligible NAb 60 against Omicron. A BNT162b2 booster (3rd dose) following heterologous CoronaVac and 61 62 ChAdOx1 regimens induced >140-fold increase in NAb titres against Omicron. Our findings indicate that heterologous regimens using BNT162b2 as the second dose may be considered an 63 alternative schedule to maximize immune response. 64 65 66 67 68 69 70 71 72 73

- 74
- 75

76 Introduction

As of 22nd of Feb 2022, the severe acute respiratory syndrome coronavirus-2 (SARS-77 CoV-2) has infected more than 400 million people and caused more than 5 million deaths 78 globally¹. Vaccination against COVID-19 has been crucial for controlling the pandemic, with 79 9 COVID-19 vaccines receiving World Health Organization (WHO) Emergency Use listing 80 (EUL) to date. The ChAdOx1 (a chimpanzee adenovirus-vectored vaccine expressing the 81 82 SARS-CoV-2 spike protein, Oxford University-AstraZeneca), BNT162b2 (SARS-CoV-2 spike protein mRNA vaccine, Pfizer-BioNTech, US-Germany) and CoronaVac (an inactivated 83 84 whole-virion SARS-CoV-2 vaccine, Sinovac Life Science, China) are the most widely used COVID-19 vaccines globally; ChAdOx1 and CoronaVac are used in many low- and middle-85 income countries^{2,3}. All three vaccines given as 2-dose primary schedule were demonstrated to 86 87 be safe and effective in preventing symptomatic COVID-19 and severe disease caused by the ancestral SARS-CoV-2 Wuhan strain as well as Alpha, Beta and Delta variants⁴. The SARS-88 CoV-2 Omicron variant identified in late 2021 was found to harbour 36 mutations in the spike 89 protein which enable the virus to evade immunity induced by infection or vaccination. Many 90 studies suggested that a booster dose is needed to protect against Omicron⁵⁻⁸. 91

92

Although the level of neutralising antibodies to protect against infection or severe disease has not been identified, it is clear that neutralising antibodies correlate with vaccine effectiveness and are believed to be the primary mechanism of protection against SARS-CoV-2 infection⁹. Other aspects of the immune response, in particular cellular immunity, are also likely to be important in protection particularly against severe disease and are important to measure following COVID-19 vaccination.

The limited supply of COVID-19 vaccines globally has resulted in less than 10% of the 100 eligible population in low-income countries being fully vaccinated¹⁰. Heterologous COVID-19 101 vaccination or mix-and-match COVID-19 vaccine schedules would alleviate the vaccine 102 supply issues and allow more flexible COVID-19 vaccination in these settings. However, such 103 strategies need to be demonstrated to be equally safe and immunogenic compared with current 104 homologous COVID-19 vaccination. While some studies that reported similar or higher 105 106 immunogenicity following heterologous primary vaccination involving the mRNA vaccines (BNT162b2 and mRNA-1273: SARS-CoV-2 spike protein mRNA vaccine, Moderna, US) and 107 ChAdOx1¹¹ compared to homologous vaccination¹², limited data is available for heterologous 108 primary vaccination involving inactivated vaccines such as CoronaVac. 109

110

In Thailand, due to the lack of access to mRNA vaccine in the early phase of the 111 pandemic, and following early reports of better immunogenicity in heterologous primary series 112 than homologous primary series, a CoronaVac-prime and ChAdOx1-boost schedule has been 113 implemented across the country¹³. However, limited data exists for how these vaccine 114 schedules, as well as following an additional dose of vaccine might protect against the Delta 115 and Omicron variants. We evaluated the reactogenicity and immunogenicity of heterologous 116 COVID-19 primary vaccine schedules involving BNT162b2, ChAdOx1 or CoronaVac, as well 117 as BNT162b2 boosting in participants who received ChAdOx1 and CoronaVac as primary 118 119 series.

120

121 **Results**

122 Participant's baseline characteristics

Between January 2021- June 2021, a total of 220 participants were screened and 210
were enrolled. Participants were assigned to one of the seven groups (30 per group) of either

two-dose homologous BNT162b2 or heterologous combinations of CoronaVac, ChAdOx1 and 125 BNT162b2 (CoronaVac-ChAdOx1, CoronaVac-BNT162b2, 126 ChAdOx1-CoronaVac, 127 ChAdOx1-BNT162b2, BNT162b2-CoronaVac, BNT162b2-ChAdOx1). Among the participants, eight participants were infected with SARS-COV-2 at baseline, defined by 128 positive anti-nucleoprotein antibody (anti-NP IgG) and were excluded from the analysis, while 129 one participant was lost to follow up (Figure 1). The overall median (range) age of study 130 131 participants were 38 (19-60) years old, and 108/210 (51.43%) were female. The baseline 132 characteristics were similar across the seven groups (Table 1).

133

134 SARS-CoV-2 IgG response against ancestral virus following heterologous primary series

All participants from each group seroconverted at 4 weeks after the first dose. At 2 135 weeks after the second dose, the virus-specific IgG levels were highest among the groups who 136 received BNT162b2 as second dose (Figure 2A): CoronaVac-BNT162b2 (2181.8 BAU/mL, 137 95%CI 1558.2 to 3055.1) and ChAdOx1-BNT162b2 groups (2132.7 BAU/mL, 95%CI 1696.1 138 to 2,681.7); both groups have similar IgG levels compared with the homologous BNT162b2-139 BNT162b2 group (2248.8 BAU/mL, 95%CI 1691.3 to 2,990.0). These levels were 140 significantly higher compared with the groups who received ChAdOx1 or CoronaVac as 141 second dose (CoronaVac-ChAdOx1: 851.4 BAU/mL, 95%CI 649.5 to 1116.1; BNT162b2-142 ChAdOx1: 1201.2 BAU/mL, 95%CI 947.9 to 1522.1; ChAdOx1- CoronaVac: 137.04 143 BAU/mL, 95%CI 103.6 to 186.4; BNT162b2-CoronaVac: 225.2 BAU/mL, 95%CI 177.1 to 144 286.4) (Figure 2 and Supplementary Table 1). Based on our previous data on homologous 145 ChAdOx1 or CoronaVac primary series at 2 weeks after the second dose¹⁴ heterologous 146 schedule with ChAdOx1 as second dose (CoronaVac-ChAdOx1or BNT162b2-ChAdOx1) 147 induced significantly higher IgG than the homologous ChAdOx1 or CoronaVac schedules 148 (p<0.0001). In contrast, similar or lower IgG levels were observed with heterologous schedule 149

with CoronaVac as second dose (ChAdOx1-CoronaVac or BNT162b2-CoronaVac) (Figure 2
and Supplementary Table 1). The geometric mean ratio (GMR) from dose 1 to dose 2 were
highest in those that received CoronaVac as first dose and received either ChAdOx1 (55-fold)
or BNT162b2 (110-fold) as second dose. The GMR ratio between dose 1 and 2 in groups that
received CoronaVac as the second dose (ChAdOx1-CoronaVac and BNT162b2-CoronaVac)
was the lowest (approximately 1.6-fold) (Supplementary Table 1).

156

At 10-12 weeks post-second dose, there was around 3- to 4-fold decrease in IgG levels across all groups (Figure 2 and Supplementary Table 1). The groups that received CoronaVac as the second dose had IgG levels significantly lower than the levels found at 4 weeks post first dose (p<0.0001).

161

162 Neutralizing antibody responses against SARS-CoV-2 variants (Delta, Beta and Omicron)
163 following heterologous primary series

Neutralizing antibodies (PRNT₅₀) against the Delta and Beta SARS-CoV-2 variants for 164 each group were measured at 2 weeks after the second dose using plaque-reduction 165 neutralization test (Figure 3). Similar to the IgG response against the ancestral Wuhan strain, 166 the groups whom were given BNT162b2 as second dose had significantly higher PRNT₅₀ 167 against Delta and Beta than the groups that received ChAdOx1 or CoronaVac as the second 168 dose (PRNT₅₀ geometric mean titres (GMT) for Delta: BNT162b2 groups 195.12-196.97 169 (95%CI 126.9 to 305.7), ChAdOx1 groups 78.65-112.36 (95%CI 57.1 to 147.1), CoronaVac 170 groups 20.36-22.69 (95%CI 14.2 to 32.2), p<0.001; PRNT₅₀ for Beta: BNT162b2 groups 171 43.28-62.36 (95%CI 28.9 to 101.6), ChAdOx1 groups 20.43-30.56 (95%CI 14.4 to 50.4), 172 CoronaVac groups, 8.18-9.01 (95%CI 6.5 to 11.2), p<0.001) (Figure 3A and Supplementary 173 Table 1). The PRNT₅₀ in the heterologous groups that received BNT162b2 as second dose were 174

similar to those in the homologous BNT162b2 group. For all groups, PRNT₅₀ against the Beta
variant were reduced by 2 to 5-fold compared to the Delta variant (Supplementary Table 1).

177

Due to the unavailability of live-virus assay against Omicron, we used pseudovirus-178 based neutralization assay to evaluate neutralizing antibody activity against Omicron and Delta 179 180 to compare the two variants. There was a strong correlation between the $PVNT_{50}$ and $PRNT_{50}$ 181 titres against Delta (r=0.79) (Supplementary Figure 1). At 2 weeks after the second dose, the seropositivity rate (defined as >1:10 PVNT₅₀) against Omicron among groups who received 182 183 BNT162b2, ChAdOx1, and CoronaVac as second dose were 80% (45/56), 50% (30/60), and 21% (12/58), respectively. as the seropositivity rate was 62% (18/29) for the homologous 2-184 dose BNT162b2 group. Overall, PVNT50 against Omicron was low across the groups and were 185 28- to 229-fold lower than Delta, depending on the vaccine schedules (Figure 3B and 186 Supplementary Table 1). The PVNT₅₀ against both Delta and Omicron were significantly lower 187 188 among groups who received CoronaVac as second dose compared to the other groups

189

190 Interferon gamma responses following heterologous primary series

The interferon gamma response was measured using the interferon gamma release assay
(IGRA) as a surrogate for SARS-CoV-2-specific T cell responses. At 2 weeks after the second
dose, groups who received BNT162b2 as second dose (>80% of participants, including
homologous BNT162b2 group) had the highest IGRA positivity rate, followed by the groups
who received ChAdOx1 (66-73%) and CoronaVac (55-59%) (Figure 4 and Supplementary
Table 2). The IGRA levels are shown in Supplementary Figure 2.

197

198 Immunogenicity of BNT162b2 booster (3rd dose) vaccination in the groups that received
199 heterologous CoronaVac and ChAdOx1 in the primary series

Based on the relatively lower immunogenicity observed in the groups of CoronaVac-200 ChAdOx1 and ChAdOx1-CoronaVac, and the relevance of these schedules for Thailand and 201 other LMICs, we investigated the immunogenicity of a BNT162b2 booster given at 10-12 202 weeks after the second dose. At two weeks after the booster dose, the virus-specific IgG levels 203 against the ancestral strain were similar between the CoronaVac-ChAdOx1 and ChAdOx1-204 CoronaVac groups (2518.8, 95%CI: 1960.4, 3236.4 BAU/mL and 2610.6, 95%CI 2037.7-205 206 3344.5 BAU/mL, respectively, p=0.84) (Figure 4A and Supplementary Table 1). However, the GMR between two weeks post 3rd and two weeks post 2nd dose were 2.5 and 18.9 for 207 208 CoronaVac-ChAdOx1-BNT162b2 and ChAdOx1-CoronaVac-BNT162b2 groups, respectively (Supplementary Table 1). 209

210

211 Consistent with this observation, two weeks after a BNT162b2 booster, neutralizing 212 antibodies against Omicron were 145.8- and 1150.6-fold higher than two weeks after the 213 second dose for CoronaVac-ChAdOx1-BNT162b2 and ChAdOx1-CoronaVac-BNT162b2 214 groups, respectively (Figure 4B and Supplementary Table 1). Notably, the ChAdOx1-215 CoronaVac-BNT162b2 group had higher neutralising antibodies against Delta and Omicron 216 than CoronaVac-ChAdOx1-BNT162b2 group (Supplementary Table 1). Neutralising antibody 217 titres against Omicron were around 2-3-fold lower than against Delta.

218

219 Reactogenicity of second dose and third dose following heterologous vaccination

The overall adverse events (AE) reported for all groups following the second dose were mild to moderate, with no serious AE reported (Figure 5). Systemic reactions were most frequent among those who received CoronaVac-ChAdOx1 (97%, 29/30), while similar local reactions were observed between those who received BNT162b2 as the second dose, as well as those who received CoronaVac-ChAdOx1 schedule (87%-93%). Those who received CoronaVac as the second dose had significantly lower local reactions (45-53%) or systemic reactions (48-67%) compared to the other groups. The most frequently reported systemic reactions among all the study groups were fatigue, myalgia and headaches. The AE reported after the BNT162b2 booster (third) dose was similar to that reported after the BNT162b2 second dose.

230

231 Discussion

Heterologous vaccination may improve the immunogenicity and flexibility of vaccine 232 233 schedules, particularly when the supply of a vaccine is limited. Our findings showed that heterologous schedules involving BNT162b2, ChAdOx1 and CoronaVac are safe, but their 234 immunogenicity varied depending on the type of vaccine given as the second dose. Of note, 235 using BNT162b2 as the second dose, regardless of the vaccine type given as first dose, induced 236 the highest humoral and cellular immune responses, and is equivalent to homologous 237 BNT162b2 schedules. These schedules however were poorly immunogenic against Omicron. 238 An additional dose BNT162b2 was able to boost the neutralizing antibody response against 239 Omicron in participants who received heterologous CoronaVac-ChAdOx1 or ChAdOx1-240 CoronaVac. Taken together, heterologous prime-boost schedules using BNT162b2 as the 241 second dose may improve the immunogenicity of homologous CoronaVac and ChAdOx1 242 primary series, but unlikely to protect against Omicron for which a third booster BNT162b2 is 243 244 needed.

245

Our findings on heterologous schedules involving ChAdOx1 and BNT162b2 supports earlier findings from studies predominately from Europe where priming of ChAdOx1 and boosting with BNT162b2 as the second dose induced higher humoral and cell-mediated immune responses than homologous ChAdOx1 primary series^{11,12,15-17}, and to some extent

higher cell-mediated immune responses than homologous BNT162b2 primary series. Some 250 studies have found better neutralising capacity against the SARS-CoV-2 variants and immune 251 memory responses following heterologous ChAdOx1-BNT162b2 schedule compared to 252 homologous ChAdOx1 or BNT162b2¹⁸. Whether other combinations of heterologous COVID-253 19 vaccination, including longer intervals between different vaccines can improve protection 254 against SARS-CoV-2 variants is unknown. The heterologous schedules in this study were given 255 256 4 weeks apart and are similar to the intervals for homologous BNT162b2 or CoronaVac vaccination. This interval may provide earlier protection against SARS-CoV-2 infection unlike 257 258 homologous ChAdOx1 vaccination where the intervals are generally recommended between 8-12 weeks to yield a better protection. This is particularly relevant for protection against the 259 Delta variant, where two doses of the vaccines are needed¹⁹. 260

261

While there have been data on heterologous schedules involving ChAdOx1 and 262 BNT162b2, to our knowledge, only one study has evaluated heterologous primary series 263 involving inactivated vaccine such as CoronaVac¹³. The study found higher immunogenicity 264 of CoronaVac-ChAdOx1 schedule than either homologous CoronaVac or ChAdOx1 265 vaccination¹³. Consistent with this finding, we found that CoronaVac given as the first priming 266 dose induced sufficient immune memory, which when boosted with either ChAdOx1 and 267 BNT162b2 as the second dose induced high levels of humoral and cellular immunity. However, 268 269 CoronaVac given as the second dose following first priming dose of ChAdOx1 or BNT162b2 were weakly immunogenic, raising concerns on the protection offered by such schedules. This 270 finding indicates that not all heterologous schedules improve immunogenicity, and the 271 272 immunogenicity is somewhat dependent on the sequence of certain vaccines. Further investigations of such schedules are warranted particularly for countries that have access to 273 only CoronaVac and ChAdOx1 and are considering a mix-and-match approach. 274

Homologous primary series of CoronaVac, ChAdOx1 or BNT162b2 have reduced 275 efficacy against symptomatic infection caused by SARS-CoV-2 variants, particularly the 276 Delta¹⁹⁻²¹. The clinical efficacy of heterologous schedules in this study is unknown, however 277 protection is likely to be similar or greater than homologous schedules given the association 278 between humoral responses and vaccine efficacy^{9,22}. Indeed, a recent observational study on 279 the immunogenicity and efficacy of ChAdOx1-BNT162b2 vaccination found that this 280 281 schedule provided better protection against SARS-COV-2 infection, including the variants (Omicron not tested) than the homologous $BNT162b2^{18}$. 282

283

In LMICs that have access to COVID-19 vaccines, access to mRNA vaccines are 284 limited. Heterologous primary series involving CoronaVac and ChAdOx1 if proven to provide 285 similar or better protection against SARS-CoV-2 than homologous CoronaVac or ChAdOx1 286 series will allow more flexible COVID-19 vaccination arrangement, and potentially improve 287 vaccine uptake. With improved vaccination coverage, particularly in LMICs, this would reduce 288 the chance of new variants emerging and improve global equity. Evaluation of such schedule 289 in a Thailand have revealed similar vaccine effectiveness between heterologous CoronaVac-290 ChAdOx1 schedule (74%) compared to homologous 2-dose ChAdOx1 (83%), and higher than 291 2-dose CoronaVac (60%) schedule²³. In countries where mRNA vaccines are in limited supply, 292 their use as a second dose in the primary series or third dose would have the benefit of providing 293 294 robust immunogenicity while also potentially reducing the risks of the rare side effects such as pericarditis and myocarditis which are mainly reported after the second dose of mRNA 295 vaccines^{24,25}. In addition, repeat dosing of the same viral-vector vaccine may also induce anti-296 297 vector immunity, potentially reducing the protective immune responses which can be overcome by heterologous schedule. 298

It is increasingly evident that three doses of COVID-19 vaccines with homologous 300 mRNA schedule or heterologous schedule with mRNA as booster are needed to protect against 301 the Omicron variant^{26,27}. This is in line with recent immunological studies that showed that 302 three doses of homologous mRNA schedule or heterologous schedule with mRNA as booster 303 induced high levels of neutralising antibodies against Delta and Omicron variants²⁸⁻³⁰. 304 Consistent with this finding, we found that a third dose of BNT162b2 given to participants who 305 306 received CoronaVac and ChAdOx1 primary series, in either sequence, induced high levels of neutralising antibodies against the Delta and Omicron variants. This is of interest that despite 307 308 the poorer immunogenicity of ChAdOx1-CoronaVac primary series compared to when BNT162b2 are given as second dose, the BNT162b2 given as a third dose was able to induce 309 high level humoral immunity against Omicron. This is the first study to demonstrate that 310 neutralising antibodies against SARS-CoV-2 variants following heterologous triple platform 311 vaccination supporting the mix-and-match principle in primary series and booster using 312 BNT162b2 as the final dose. 313

314

Limitations of this study were that the participants were not blinded for the study 315 vaccine, which may have influenced the reporting of adverse reactions. Secondly, the small 316 sample size in each group did not allow us to identify any potential rare AEs. However, findings 317 from this study have been used to inform the Thailand National COVID-19 vaccination 318 319 program recommendation by including the CoronaVac-ChAdOx1 regimen during the time when mRNA vaccines were not available. Ongoing surveillance of any rare AEs and the 320 clinical effectiveness of this heterologous schedule will inform the feasibility of such schedule 321 against the SARS-CoV-2 variants. Lastly, the BNT162b2 booster in this study was only given 322 to two groups who received CoronaVac and ChAdOx1, and there was no homologous three-323 dose BNT162b2 group for comparison of their immunogenicity. Despite this, it was clear that 324

BNT162b2 as the third booster vaccination provided high neutralizing activity against Delta and Omicron, which is likely to provide protection against these two predominant variants. Future studies incorporating mRNA booster to other heterologous primary schedules will be of interest, particularly with other COVID-19 vaccines that have recently received WHO EUL.

In conclusion, we found that heterologous COVID-19 primary series using either 330 331 ChAdOx1 or BNT162b2 as second dose were highly immunogenic against SARS-CoV-2 ancestral strain, Beta and Delta variants, but low neutralizing antibody against Omicron. A 332 333 third dose of BNT162b2 given to individuals who received heterologous primary series of CoronaVac and ChAdOx1 induced high neutralising antibodies against Delta and Omicron. 334 Larger studies including longer follow up are needed to validate these findings clinically and 335 evaluate the persistence of immune responses following heterologous COVID-19 vaccination. 336 Our findings have implications for countries where have implemented heterologous COVID-337 19 primary series involving CoronaVac and ChAdOx1, and in settings where there are critical 338 vaccine supply issues, particularly mRNA vaccine. 339

340

341 Method

342 Study design

This was a single-centre prospective cohort study conducted at the Clinical Research Center of the Faculty of Medicine Siriraj Hospital (SICRES), Bangkok, Thailand. Participants were openly assigned to one of six heterologous combinations of CoronaVac, ChAdOx1 and BNT162b2 groups or a homologous BNT162b2 (as control) group. For heterologous schedules, the interval between the two doses was 4 weeks. Adverse events following the second dose were recorded to determine the safety and reactogenicity. Blood samples were collected at baseline (pre-vaccination), 4 weeks after the first dose (prime), 2 weeks and 10-12 weeks following the second dose (boost) to determine immunogenicity. The clinical study was approved by the Siriraj Institutional Ethics Review Board (approval no.Si537/2021). The procedures in this study adhere to the tenets of the Declaration of Helsinki. The study was registered at http://www.thaiclinicaltrials.org/show/TCTR20210720007.

354

355 Study participants

356 Participants were healthy adults aged 18-60 years who were not known to be infected with SARS-CoV-2 or received COVID-19 vaccine other than as assigned in the study. The 357 358 exclusion criteria were unstable underlying disease, having acute illness, had a history of anaphylaxis: were pregnant females. were immunocompromised or receiving 359 immunosuppressants at screening. Participants who had a positive anti-nucleoprotein (anti-NP) 360 or anti-RBD IgG antibody at baseline were excluded. 361

362

363 *Procedures*

Participants were recruited into the study following informed consent and were 364 randomised to one of seven prime-boost groups: CoronaVac-ChAdOx1, CoronaVac-365 BNT162b2, 366 ChAdOx1-CoronaVac, ChAdOx1-BNT162b2, BNT162b2-CoronaVac, BNT162b2-ChAdOx1 or homologous BNT162b2. As mRNA booster vaccination as the third 367 dose has been included in the national COVID-10 vaccination program in Thailand, we further 368 explore the safety and immunogenicity of heterologous BNT162b2 boosting in this cohort. The 369 participants in the CoronaVac-ChAdOx1 and ChAdOx1-CoronaVac groups had low antibody 370 response based on preliminary analysis and were invited back to receive a BNT162b2 booster 371 dose at 10-12 weeks after the second dose. 372

Following each vaccination, all participants were observed for any immediate reaction 374 for at least 30 min. Participants were instructed to record self-assessments in an electronic diary 375 (eDiary) for seven days after the second dose to track adverse events (AEs), which included 376 solicited local and systemic adverse reactions. Adverse events in this study were defined as any 377 unfavourable or unintended signs, symptoms, or disease that occurs in any participant. Solicited 378 local AEs included pain, erythema, and swelling/induration at the injection site, and localized 379 380 axillary swelling or tenderness ipsilateral to the injection arm. Solicited systemic AEs include headache, fatigue, myalgia, arthralgia, nausea/vomiting, rash, fever, and chills. The severity of 381 382 solicited AEs were graded using a numerical scale from 1 to 4 based on the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical 383 Trials from the United States Food and Drug Administration (FDA)³¹. 384

385

Blood samples collected were tested for anti-receptor binding domain of SARS-CoV-2 spike protein IgG (Anti-RBD IgG) at all timepoints and T-cell response using interferongamma release assay (IGRA) at four weeks after the first dose and two weeks after the second dose. A qualitative anti-NP IgG was tested at baseline. The standard 50% plaque reduction neutralizing test (PRNT) assay and pseudovirion-based neutralizing test pseudotype-based neutralization assays (PVNT) were used to measure neutralizaing antibodies against SARS-CoV-2 variants on blood samples collected at two weeks after the second dose and third dose.

393

394 Laboratory assays:

The anti-RBD IgG was measured by chemiluminescent microparticle immunoassay using the SARS-CoV-2 IgG II Quant (Abbott, List No. 06S60) on the ARCHITECT i System. This assay linearly measures the level of antibody between 21.0 - 40,000.0 arbitrary unit (AU)/mL, which was converted later to WHO International Standard concentration as binding

antibody unit per mL (BAU/mL) following the equation provided by the manufacturer
(BAU/mL =0.142 x AU/mL). A level greater or equal to the cutoff value of 50 AU/mL or 7.1
BAU/mL was defined as seropositive. The qualitative anti-NP IgG was also measured by
CMIA using the SARS-CoV-2 IgG (Abbott, List No. 06R86) on the ARCHITECT i System.

The SARS-CoV-2 live-virus neutralisation assay (PRNT₅₀) was performed at the 404 405 Department of Medical Science, Ministry of Public Health, Bangkok, Thailand. Briefly, the Vero cells were seeded at 2x 10⁵ cells/well/ 3 ml and placed in 37°C, 5% CO₂ incubator for 1 406 407 day. Test sera were initially diluted at 1:10, 1:40, 1:160 and 1:640, respectively. SARS-CoV-2 virus (Delta and Beta variant) was diluted in culture medium to yield 40-120 plaques/well in 408 the virus control wells. Cell control wells, convalescent patient serum and normal human serum 409 were also included as assay controls. Equal volume of diluted serum and the optimal plaque 410 numbers of SARS CoV-2 virus were incubated at 37°C in water bath for 1 hr. After removing 411 the culture medium from Vero cell culture plates, 200 ul of the virus-serum antibody mixture 412 were inoculated into monolayer Vero cells. The culture plates were rocked every 15 min for 1 413 h. Three ml of overlay semisolid medium (Sigma, USA) and 10% FBS) were replaced after 414 removing excessive viruses. All plates were incubated at 37°C, 5% CO₂ for 7 days. Cells were 415 fixed with 10% (v/v) formaldehyde then stained with 0.5% crystal violet in PBS. The number 416 of plaques formed was counted in triplicate wells and percentage of plaque reduction at 50% 417 was calculated. The PRNT₅₀ of test sample was defined as the reciprocal of the highest test 418 serum dilution for which the virus infectivity is reduced by 50% when compared with the 419 average plaque counts of the virus control and was calculated by using a four-point linear 420 regression method. Plaque counts for all serial dilutions of serum were scored to ensure that 421 there was a dose response. The detection limit of PRNT₅₀ was 1:10. 422

SARS-CoV-2 pseudovirus was constructed for pseudotype-based neutralization assays 424 (PVNT). Codon-optimized gene encoding the spike of Omicron (B.1.1.529/ BA.1) and Delta 425 (B.1.617.2) were generated by gene synthesis (Genscript) and cloned into the pCAGGS 426 expressing plasmid by In-Fusion assembly (Clontech). Pseudovirus was generated and 427 concentrated as previously described (1). Briefly, Human embryonic kidney (HEK) 293T/17 428 cells were transfected with the pCAGGS-S expression vector (Delta or Omicron) in 429 430 conjunction with p8.9171 and pCSFLW72 using polyethylenimine (PEI, Polysciences, Warrington, USA). HIV (SARS-CoV-2) pseudotypes containing supernatants were harvested 431 432 72 hours post-transfection, aliquoted and frozen at -80°C prior to use.

433

PVNT were carried out as described previously³². Briefly, HEK293T cells 434 overexpressing human ACE2 were maintained in Dulbecco's modified Eagle's medium 435 (DMEM) supplemented with 10% FBS, 200mM L-glutamine, 100µg/ml streptomycin and 100 436 IU/ml penicillin. At 24 hours before the assay, cells ($5x10^5$ cells/ml cells in 10 mm dish) were 437 transfected with pCAGGS expressing codon-optimized human TMPRSS2 using Fugene HD 438 transfection reagent (Promega). Serum samples were heat-inactivated at 56°C for 30 min and 439 subsequently serially diluted from 1:40 to 1:5,120 in complete DMEM prior to incubation with 440 specified SARS-CoV-2 pseudovirus, incubated for 1 h at 37°C, and plated onto TMPRSS2-441 expressing HEK293T-ACE2 target cells (1×10^4 cells/well). After 48 h, luciferase activity was 442 quantified by the addition of Bright-GloTM luciferase substrate (Promega) and analysis on 443 Synergy[™] HTX Multi-Mode Microplate Reader (BioTek). Antibody titer was then calculated 444 by interpolating the point at which infectivity had been reduced to 50% of the value for the no 445 serum control samples using GraphPad Prism 9.0 software. 446

448	IGRA were performed using the Quantiferon SARS-CoV-2 assay (QIAGEN)
449	according to the manufacturer's instruction. Fresh whole blood samples were collected into
450	tubes containing SARS-CoV-2 S peptide pools for $CD4^+$ T cells (Ag 1), and $CD8^+$ T cells
451	(Ag2), a mitogen tube as the positive control and an unstimulated tube as negative control. The
452	specimen was incubated at 37° C for 16-24 hours and centrifuged to separate plasma.
453	Interferon-gamma (IFN- γ) concentration in the plasma fraction was measured with an
454	automated QuantiFERON SARS-CoV-2 ELISA instrument and reported in International Units
455	per mL $(IU/mL)^{33,34}$. The cut-off points for positivity were determined as the level above the
456	mean plus three standard deviations of the negative control. Using 61 negative controls at the
457	study site, the cut-offs for Ag1 and Ag2 were greater than 0.12 IU/mL and greater than 0.17
458	IU/mL, respectively. A positive response to either Ag1 or Ag2 was considered positive.

459

460 Statistical Analysis

The AE endpoints were presented as frequencies (%) and compared using Fisher's 461 exact test. The anti-RBD IgG antibody responses were presented as geometric mean 462 concentrations (GMC) with 95% confidence intervals (CI). PRNT₅₀ and PVNT₅₀ data were 463 presented as geometric mean titers (GMT) with 95% CIs. The seroconversion rates, anti-RBD 464 IgG GMCs, and neutralising antibody GMTs were compared within group and between the 465 groups using paired t test and unpaired t test. The homologous two-dose CoronaVac and 466 ChAdOx1 primary series previously reported¹⁴ were presented as referenced data. All 467 statistical analyses were conducted using STATA version 17 (StataCorp, LP, College Station, 468 TX, USA). 469

470

471 Data Availability

472	The datasets generated during and/or analyzed during the current study are available
473	from the corresponding author on reasonable request.
474	
475	Acknowledgement
476	The authors gratefully acknowledge the Siriraj Institute of Clinical Research (SICRES)
477	team for supporting the study process and all participants who took part in this study.
478	
479	Author Contributions
480	Conceptualization and Methodology, S.N., P.W., K.S., S.S., Y.J., N.M., and K.C.;
481	Formal analysis and data curation: S.N., L.J., Z.Q.T., P.V.; Project administration, S.N., K.C.;
482	Supervision, K.C.; Resources and Funding, K.C. All involved with Investigation, and Writing-
483	review and editing.
484	
485	Conflict of Interest Declaration
486	All authors declare no personal or professional conflicts of interest, and no financial
487	support from the companies that produce and/or distribute the drugs, devices, or materials
488	described in this report.
489	
490	Funding Disclosure:
491	This study was granted by the National Research Council of Thailand (N35A640368).
492	
493	
494	

497 **References**

1. Worldometer. COVID-19 Coronavirus Pandemic. 498 https://www.worldometers.info/coronavirus/ (2022). Accessed on 22nd February 2022 499 2. The New York Times. Tracking Coronavirus Vaccinations Around the World. 500 https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html 501 (2022). Accessed on 22nd February 2022 502 503 3. Mallapaty, S. et al. How COVID vaccines shaped 2021 in eight powerful charts. *Nature* 600, 580-583 (2021). 504 505 4. Liu, Q, et al. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. Infect. Dis. Poverty 10, 132 (2022). 506 Garcia-Beltran, W. F. et al. mRNA-based COVID-19 vaccine boosters induce 5. 507 neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 185, 457-466 508 (2022). 509 Pajon, R. et al. SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 510 6. Booster Vaccination. N. Engl. J. Med. Online ahead of print. (2022). 511 Angkasekwinai, N. et al. The immunogenicity and safety of different COVID-19 7. 512 booster vaccination following CoronaVac or ChAdOx1 nCoV-19 primary series. 513 medRxiv preprint doi: https://doi.org/10.1101/2021.11.29.21266947 (2022). 514 8. Barda, N. et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 515 vaccine for preventing severe outcomes in Israel: an observational study. Lancet 398, 516 2093-2100 (2021). 517 9. Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune 518 protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205-1211 (2021). 519

520	10.	ONE.	The	astoundingly	unequal	vaccine	rollout.
521		https://ww	vw.one.org/a	frica/issues/covid-19	-tracker/explore	-vaccines/	(2022).
522		Accessed	on 25 th Febr	uary 2022.			

- Liu, X. et al. Safety and immunogenicity of heterologous versus homologous primeboost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-
- 525 COV): a single-blind, randomised, non-inferiority trial. *Lancet* **398**, 856–869 (2021).
- 526 12. Schmidt, T. et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV527 19/mRNA vaccination. *Nat. Med.* 27, 1530–1535 (2021).
- Yorsaeng, R. et al. Immune response elicited from heterologous SARS-CoV-2
 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria). medRxiv
 preprint doi: https://doi.org/10.1101/2021.09.01.21262955 (2021).
- 53114.Angkasekwinai, N. et al. Safety and Immunogenicity of CoronaVac and ChAdOx1532Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai533HealthcareWorkers.534https://doi.org/10.1101/2021.10.03.21264451 (2022).
- 535 15. Groß, R. et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost
 536 vaccination elicits potent neutralizing antibody responses and T cell reactivity
 537 *eBioMedicine* **75**, 103761 (2021).
- Barros-Martins, J. et al. Humoral and cellular immune response against SARS-CoV-2
 variants following heterologous and homologous ChAdOx1 nCoV-19/BNT162b2
 vaccination. medRxiv preprint doi: https://doi.org/10.1101/2021.06.01.21258172
 (2021).
- 542 17. Borobia, A. M. et al. Immunogenicity and reactogenicity of BNT162b2 booster in
 543 ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised,
 544 controlled, phase 2 trial. *Lancet* **398**, 121–130 (2021).

- 545 18. Pozzetto, B. et al. Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2
 546 vaccination. *Nature* 600, 701–706 (2021).
- 547 19. Berna, J. L. et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta)
 548 Variant. *N. Engl. J. Med.* 385, 585-594 (2021)
- Vacharathit, V. et al. CoronaVac induces lower neutralising activity against variants of
 concern than natural infection. *Lancet. Infect. Dis.* 21, 1352-1354 (2021).
- AlQahtani, M. et al. Morbidity and mortality from COVID-19 postvaccination
 breakthrough infections in association with vaccines and the emergence of variants in
- 553Bahrain.https://assets.researchsquare.com/files/rs-
- 554 <u>828021/v1_covered.pdf?c=1631876901</u>. Accessed on 25th February 2022.
- Angyal, A. et al. T-cell and antibody responses to first BNT162b2 vaccine dose in
 previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre
 prospective cohort study. *Lancet Microbe.* 3, e21–31 (2022).
- Sritipsukho, P. et al. Comparing real-life effectiveness of various COVID-19 vaccine
 regimens during the delta variant-dominant pandemic: a test-negative case-control
 study. *Emerg. Microbes. Infect.* 11, 585-592 (2022).
- 561 24. Mevorach, D. et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in
 562 Israel. *N. Engl. J. Med.* 385, 2140-2149 (2021).
- 563 25. Bozkurt, B. et al. Myocarditis With COVID-19 mRNA Vaccines. *Circulation* 144, 471564 484 (2021).
- Accorsi, E. K. et al. Association Between 3 Doses of mRNA COVID-19 Vaccine and
 Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. *JAMA* 327, 639-651 (2022).
- Ferdinands, J. M. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines
 Against COVID-19–Associated Emergency Department and Urgent Care Encounters

570	and Hospitalizations Among Adults During Periods of Delta and Omicron Variant
571	Predominance — VISION Network, 10 States, August 2021–January 2022. MMWR 71,
572	255–263 (2022).

- 573 28. Clemens, S. A. C. et al. Heterologous versus homologous COVID-19 booster
 574 vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in
 575 Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. *Lancet*576 **399**, 521-529 (2022).
- 577 29. Cheng, S. M. S. et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant
 578 BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination.
- 579 *Nat. Med.* https://doi.org/10.1038/s41591-022-01704-7 (2022).
- 30. Pérez-Then, E. et al. Neutralizing antibodies against the SARS-CoV-2 Delta and
 Omicron variants following heterologous CoronaVac plus BNT162b2 booster
 vaccination. *Nat. Med.* https://doi.org/10.1038/s41591-022-01705-6 (2022).
- U.S. Department of Health and Human Services, Food and Drug Administration,
 Center for Biologics Evaluation and Research. Guidance for Industry Toxicity Grading
 Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine
 Clinical Trials. https://www.fda.gov/media/73679/download (2007).
- 587 32. Koonpaew, S. et al. A Single-Cycle Influenza A Virus-Based SARS-CoV-2 Vaccine
 588 Elicits Potent Immune Responses in a Mouse Model. *Vaccines* 9, 850 (2021).
- Murugesan, K. et al. Interferon-γ Release Assay for Accurate Detection of Severe Acute
 Respiratory Syndrome Coronavirus 2 T-Cell Response. *Clin. Infect. Dis.* 73, e3130e3132 (2021).
- Martínez-Gallo, M. et al.Commercialized kit to assess T-cell responses against SARSCoV-2 S peptides. A pilot study in Health Care Workers. *medRxiv* preprint
 https://doi.org/10.1101/2021.03.31.21254472 (2021).

595

596 Figure legends

597 Fig. 1 Consort flow diagram describing the allocation and number of analyzed

598 participants in each study group.

599 Fig. 2 Anti-SARS-CoV-2 receptor binding domain (RBD) IgG at 4 weeks after the first

dose, and 2 and 10-12 weeks after the second dose. Numbers in the graph represent

601 geometric mean concentration (GMC) and the error bars represent 95% confidence

602 interval. Dotted lines represent the GMC (95% CI) of anti-SARS-CoV-2 RBD IgG at 2

weeks after the second dose of homologous primary series of CoronaVac and ChAdOx1

reported by our study group using the same laboratory method and facility as this study⁴.

605 Unpaired t-test were used to compare IgG GMC between groups at two weeks after

606 second dose vaccination.

607 Fig. 3 Neutralizing antibody titers against SARS-CoV-2 variants at two weeks after

608 second dose. (A) Plaque reduction neutralization titers (PRNT₅₀) against Delta (blue) and

Beta (red) variants. The dot line referred to the geometric mean tires at 2 weeks after the

second dose of homologous CoronaVac or ChAdOx1 reported by our group using the

same laboratory methods and facility with this study⁴. (B) Pseudovirus-based

612 neutralizing antibody titers (PVNT₅₀) against Delta (blue) and Omicron variants (red).

613 Numbers on the x-axis represent geometric mean titer (GMT) and error bars represent

614 95% confidence interval (CI). Unpaired t-test were used to compare PRNT₅₀ between

615 each group at two weeks after second dose.

Fig. 4 Humoral immune response following a BNT162b2 booster (3rd dose) vaccination

in the groups that received heterologous CoronaVac and ChAdOx1 in the primary series.


618 (A) anti-SARS-CoV-2 receptor binding domain (RBD) IgG kinetics at two weeks after second


dose (pink), 12 weeks after second dose (blue), and two weeks after the third booster dose


(orange). (B) Pseudovirus-based neutralizing antibody titres (PVNT50) against Delta (blue) 620 and Omicron (green) variants following a BNT162b2 booster (third dose) at two weeks after 621 second dose and two weeks after the third booster dose. Numbers on the x-axis represent 622 geometric mean titer. The fold change and significance p-value comparing two weeks after the 623 third booster and two weeks after second dose. 624 Fig. 5 Proportion of interferon-gamma release assay (IGRA)-positivity rate at four weeks 625 626 after the first dose and two weeks after the second dose. IGRA-positive is defined as positive response to either antigen 1 (Ag1) or antigen 2 (Ag2) of the assay. The proportions of 627 628 IGRA positive following the first dose vaccination in the groups that received the same vaccine were not significantly different. 629 Fig. 6 Adverse events following second dose and third dose. Stacked bars represents the 630 proportion of participants who reported mild and moderate adverse events. 631 Supplementary Fig. S1 Correlation between plaque-reduction neutralization test 632 (PRNT50) and pseudovirus-based neutralization test (PVNT50) against Delta variant. r= 633 0.78. p<0.0001 634 Supplementary Fig. S2 Interferon-gamma (IFN-γ) responses at 4 weeks and 2 weeks after 635 first and second vaccine dose, respectively. Interferon-gamma (IFN- γ) concentration 636 were measured in blood after stimulation with SARS-CoV-2 peptide pool for CD4+ T 637 cells (Ag 1) (A), and CD8+ T cells (Ag2) (B). Data presented as International Units per 638 mL (IU/mL). 639 640 641 642 643 644

Table 1. Baseline characteristics of study participants

The groups by vaccine used as the first and second dose							
					BNT162b2 - CoronaVac		- BNT162b2 - BNT162b2
Numbers of enrolled participants	n=30	n=30	n=30	n=30	n=30	n=30	n=30
Age (years),	39	30.5	40.5	39	34.5	32.5	36.5
median, IQR	(33, 46)	(24, 38)	(36, 48)	(29, 43)	(25, 47)	(26, 41)	(32, 43)
Female, n (%)	15 (50)	18 (60)	14 (46.67)	19 (63.33)	13 (43.3)	16 (53.3)	13 (43.3)
BMI,	25.25	23.40	23.5	20.95	24.15	24.35	24.30
median (IQR)	(22.70, 28.10)	(21.00, 26.50)	(21.30, 26.00)	(19.60, 24.50)	(20.10, 27.70)	(20.80, 28.70)	(21.40, 26.10)
Hypertensio n, n (%)	1 (3.33)	0	4 (13.33)	1 (3.33)	0	2 (6.67)	0
Dyslipidemi a, n (%)	0	0	2 (6.67)	0	0	2 (6.67)	0
Diabetes, n (%)	0	0	1 (3.33)	0	0	0	0







BNT162b2

ose	
nd dose	

Figure 3





Figure 4


A



- 2 weeks after 2nd vaccination
- 12 weeks after 2nd vaccination
- 2 weeks after 3rd vaccination

.04	44.20	2,610.58
189.47)	(32.18, 58.89)	(2037.70, 3344.52)





Delta

- 2 weeks after 2nd vaccination
- 2 weeks after 3rd vaccination

Omicron

- 2 weeks after 2nd vaccination
- 2 weeks after 3rd vaccination




Figure 6

